← FDA DRUG APPROVALS

FDA ANDA · ANDA203835

LOSARTAN POTASSIUM

Sponsor: HETERO LABS LTD V

APPLICATION
ANDA203835
TYPE
ANDA
ORIGINAL APPROVAL
2015-08-12
LATEST ACTION
2025-12-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 25MG · TABLET · ORAL
LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 50MG · TABLET · ORAL

Approval history

2025-12-16Labeling · Supplement 21 · standardAP
2022-07-14Labeling · Supplement 15 · standardAP
2019-04-04Labeling · Supplement 4 · standardAP
2016-06-10Labeling · Supplement 1 · standardAP
2015-08-12UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →